Abstract
Biogen Idec is a global research-based company focused on the
development, manufacture and commercialisation of novel therapeutics for human
health care. Biogen Idec' s headquarters in Cambridge, MA, is strategically
close to the renowned research institutions of Harvard, the Massachusetts
Institute of Technology, the Whitehead Institute, as well as Novartis' new
research HQ and scores of smaller biotech companies. From its headquarters and
facilities across the globe, Biogen Idec' s marketed products reach patients in
more than 90 countries worldwide.
Biogen Idec is gaining a reputation as one of the leading biotechnology
innovators, particularly in the fields of cancer and immunology. Compared to
the other ' big pharma' players it is still relatively small and its marketing
organisation lacks scope and maturity. Traditionally, Biogen Idec has sought
out partners to achieve its marketing goals and it has done particularly well
from its agreement with Roche/Genentech for Rituxan.
The failure of the company to attract a takeover offer from the major
pharmaceutical companies in 2007, means that Biogen Idec will remain an
independent company for the time being. Potential bidders may have been put
off by the escalating share price, or the risky bet on Biogen Idec and Elan' s
multiple sclerosis drug, Tysabri, following its linking to a rare brain
infection that could reduce the drug' s market potential. The successful
re-launch and uptake of Tysabri may go some way to allay these fears.
Of its key products, Avonex remains the main growth driver alongside Rituxan,
supported by the re-launch of Tysabri for multiple sclerosis (MS).
The group' s core asset is its strong pipeline of middle- to late-stage drugs.
The pipeline contains some promising line-extensions and biologics for
lymphoma, leukaemia and immune disease such as MS, Crohn' s disease and
rheumatoid arthritis. Of particular note are lumiliximab, which could be the
next new medication for chronic lymphocytic leukaemia, galiximab for
non-Hodgkin' s lymphoma, lixivaptan for heart failure, BG-12 for MS and
ocrelizumab, which has the potential to take over from Rituxan in rheumatoid
arthritis as well as being used in combination with Rituxan for MS.
These projects may yet make an attractive proposition to any potential
suitors, however, should Biogen Idec go it alone, then it will need to enhance
its in-house sales and marketing capabilities to successfully bring these to
the widest possible market, allowing it to take on more responsibility for its
own destiny and to ensure it can achieve organic growth without relying on
other potentially competitive companies.
This new strategic analysis report Biogen Idec: Pipeline " Products "
Performance " Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D Projects
- Other Factors Affecting the Bottom Line
- Conclusions/Outlook
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- ONCOLOGY
- Marketed Products
- R&D Projects
- BIIB021
- BIIB022
- GA101
- Galiximab
- Lumiliximab
- Volociximab
- Growth Forecast
- CENTRAL NERVOUS SYSTEM
- Marketed Products
- R&D Projects
- BIIB014
- BG-12
- Daclizumab
- Fampridine-SR
- Neublastin
- PEGylated Interferon beta-1a (PEG IFN)
- Growth Forecast
- IMMUNOLOGY
- Marketed Products
- R&D Projects
- Growth Forecast
- OTHERS
- R&D Projects
- Adentri
- Aviptadil
- FIX:Fc
- Lixivaptan
- Long-acting recombinant Factor VIII
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDI X 2 - KEY CO RPORATE EVENTS
- APPENDI X 3 - KEY AGREEMENTS
- Alnylam Pharmaceuticals Inc
- Amorfix Life Sciences Ltd
- Astellas Pharma
- Bayer
- Biovitrum AB
- Brain Science Institute, Johns Hopkins University
- Cardiokine Biopharma LLC
- Cell Therapeutics Inc
- Celltech Group Plc
- Chemical Diversity Labs Inc
- Dyax Corp
- Fumedica GmbH
- Genaissance Pharmaceuticals Inc
- Gene Network Sciences Inc
- GlycoFi Inc
- ImmunoGen Inc
- Lexicon Genetics Inc
- Merck & Co
- mondoBIOTECH AG
- MorphoSys AG
- NeoGenesis Pharmaceuticals Inc
- Neurimmune SubOne AG
- PDL BioPharma Inc/Ophthotech Corp
- Pharmaceutical Product Development Inc (PPD)
- Rentschler Biotechnologie GmbH
- Roche
- Sunesis Pharmaceuticals Inc
- Tanox Inc
- The Medicines Company
- UCB
- Vernalis Plc
- Xenogen Corp
- APPENDI X 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint Ventures
- APPENDI X 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Sales By Business Segment
- Sales By Geographic Area
- Product Sales By Geographic Area
- Long-Term Assets By Geographical Area
- Recent Product Approvals
- Major Therapeutic Areas And Sales
- Major Oncology Products, 2008
- Major Central Nervous System Products, 2008
- Major Immunology Products, 2008
INDEX OF CHARTS
- Sales By Business Area
- Sales By Geographic Area
- Product Sales By Geographic Area
- Long-Term Assets By Geographical Area
- Sales of Top 4 Products (2003A-2013E)
- Sales of Top Products, 2008
- Rituxan Sales (2003A-2013E)
- Avonex Sales (2003A-2012E)
- Tysabri Sales (2003A-2013E)
- Rituxan Sales (2002A-2012E)
- Ocrelizumab Sales (2011E-2015E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
